Published in Sci Rep on March 03, 2017
Apoptosis: a review of programmed cell death. Toxicol Pathol (2007) 17.92
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer (2007) 6.18
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
The lipocalin protein family: structure and function. Biochem J (1996) 5.24
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res (2010) 4.77
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
An iron delivery pathway mediated by a lipocalin. Mol Cell (2002) 3.38
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut (2012) 2.91
Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg (1998) 2.81
Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol (2002) 2.70
Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg (2000) 2.43
The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer (2014) 2.41
Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol (2013) 2.16
Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol (2011) 1.97
Cholangiocarcinoma: current concepts and insights. Hepatology (2003) 1.96
Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat (2007) 1.85
Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg (2002) 1.75
Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer (2007) 1.63
The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol (1997) 1.53
E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res (2004) 1.50
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res (2008) 1.45
Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg (1997) 1.36
The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A (2008) 1.35
Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer (2006) 1.30
Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys (2011) 1.28
Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res (2005) 1.28
Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg (1999) 1.17
Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget (2014) 1.14
Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin. Exp Dermatol (2002) 1.14
Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities. Oncogene (1998) 1.12
Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem (2009) 1.02
Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis (2009) 1.00
Efficient synthesis of 2-modified 1alpha,25-dihydroxy-19-norvitamin D3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. J Org Chem (2003) 0.99
The anti-cancer actions of vitamin D. Anticancer Agents Med Chem (2013) 0.98
NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis (2010) 0.98
The future of vitamin D analogs. Front Physiol (2014) 0.93
19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids (2011) 0.92
Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases. Int J Hepatol (2010) 0.92
Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res (2009) 0.91
Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. Cancer (2007) 0.91
Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo. Cell Cycle (2013) 0.89
Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol (2009) 0.89
Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. J Steroid Biochem Mol Biol (2011) 0.86
MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro. J Steroid Biochem Mol Biol (2013) 0.86
MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1α,25-Dihydroxyvitamin D(3) in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer Cells. Evid Based Complement Alternat Med (2012) 0.85
MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase. J Steroid Biochem Mol Biol (2013) 0.84
Recent results on A-ring modification of 1alpha,25-dihydroxyvitamin D3: design and synthesis of VDR-agonists and antagonists with high biological activity. Curr Top Med Chem (2006) 0.81
22-oxa-1,25-dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculture of cholangiocarcinoma. Cancer (2010) 0.81
Chemopreventive and chemotherapeutic effect of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model. Oncotarget (2014) 0.81
Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells. Cancer Lett (2016) 0.79
MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. Cancer Lett (2015) 0.79
Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells. PLoS One (2014) 0.79
MART-10, the new brand of 1α,25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro. J Steroid Biochem Mol Biol (2015) 0.78
MART-10, the new brand of 1α,25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro. J Steroid Biochem Mol Biol (2015) 0.78